Breast cancer
Conditions
Interventions
Gold Standard:Breast cancer pathological tissue samples and the pathological evaluation criteria of neoadjuvant treatment for breast cancer
Histopathological specimens include biopsy pathological spec
Clinical 
and 
parameters
Will 
be 
included: 
menstrual 
status, 
of 
Sponsors
The First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
Female
Age
25 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Patients with stage II-III breast cancer confirmed by pathological biopsy; (2) Complete pathological classification and grading, TNM staging, immunohistochemical tests (including ER, PR, HER2, Ki67) and related biochemical index tests (CEA, CA15-3 and CA125) before surgery; (3) No other treatment before neoadjuvant treatment; (4) Experience complete and standardized neoadjuvant treatment; (5) Perform surgery after neoadjuvant treatment and obtain pathological information; (6) MRI images (including plain scan T1WI, T2WI and DCE, DWI, T2 Mapping) were collected by uniform standards before neoadjuvant treatment, after one cycle of treatment, and before surgery. The post-treatment images were taken within one week before surgery after neoadjuvant treatment.
Exclusion criteria
Exclusion criteria: (1) Related indicators before and after neoadjuvant therapy are incomplete; (2) The neoadjuvant treatment is not completed or the plan is not standardized; (3) Did not undergo surgery or cannot obtain postoperative pathological information; (4) The imaging examination is not standardized, the data is incomplete, or the image quality does not meet the analysis standard.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRI functional parameters and radiomic parameters;Clinical pathological indicators; | — |
Countries
China
Contacts
Public ContactLina Zhang
The First Affiliated Hospital of China Medical University
Outcome results
None listed